Page last updated: 2024-08-24

irinotecan and arq 197

irinotecan has been researched along with arq 197 in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Adjei, AA; Garmey, E; Schwartz, B	1
Barni, S; Bendell, JC; Bessudo, A; Bolotin, E; Eng, C; Gladkov, O; Hart, LL; Hsu, C; Kopp, MV; Kotiv, B; Langdon, R; Müller, L; Schwartz, B; Severtsev, A; Vladimirov, V; von Roemeling, R	1

Trials

1 trial(s) available for irinotecan and arq 197

Article	Year
A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy. International journal of cancer, 2016, Jul-01, Volume: 139, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Proto-Oncogene Proteins p21(ras); Pyrrolidinones; Quinolines	2016

Article

Year

A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy.

International journal of cancer, 2016, Jul-01, Volume: 139, Issue:1

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Proto-Oncogene Proteins p21(ras); Pyrrolidinones; Quinolines

2016

Other Studies

1 other study(ies) available for irinotecan and arq 197

Article	Year
Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers. The oncologist, 2011, Volume: 16, Issue:6 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Hepatocyte Growth Factor; Humans; Irinotecan; Mice; Neoplasms; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinazolines; Quinolines; Randomized Controlled Trials as Topic; Receptors, Growth Factor	2011

Article

Year

Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers.

The oncologist, 2011, Volume: 16, Issue:6

Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Hepatocyte Growth Factor; Humans; Irinotecan; Mice; Neoplasms; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinazolines; Quinolines; Randomized Controlled Trials as Topic; Receptors, Growth Factor

2011